Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 579 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Mineralys Therapeutics, Inc.
Market Cap
$1.99B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$1.99B
Net Profit Margin
-13.36%
TTM Avg
-6.14%
3Y Avg
-11.71%
5Y Avg
-14.87%
Market Cap
$1.99B
Net Profit Margin
15.03%
TTM Avg
11.31%
3Y Avg
2.06%
5Y Avg
-9.89%
Market Cap
$1.99B
Net Profit Margin
100.84%
TTM Avg
51.96%
3Y Avg
-5.31%
5Y Avg
-103.82%
Market Cap
$2.01B
Net Profit Margin
-40.90%
TTM Avg
5.22%
3Y Avg
-37.29%
5Y Avg
-215.44%
Market Cap
$1.95B
Net Profit Margin
-20.02%
TTM Avg
-19.08%
3Y Avg
-29.38%
5Y Avg
-13.21%
Market Cap
$1.95B
Net Profit Margin
-3059.99%
TTM Avg
-3150.18%
3Y Avg
-1765.57%
5Y Avg
-1177.05%
Market Cap
$1.94B
Net Profit Margin
-15.82%
TTM Avg
-37.57%
3Y Avg
-42.30%
5Y Avg
-41.11%
Market Cap
$2.05B
Net Profit Margin
-36.51%
TTM Avg
-21.30%
3Y Avg
-316.14%
5Y Avg
-299.31%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.99B | 0.00% | 0.00% | 0.00% | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.99B | -13.36% | -6.14% | -11.71% | -14.87% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.99B | 15.03% | 11.31% | 2.06% | -9.89% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $1.99B | 100.84% | 51.96% | -5.31% | -103.82% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.01B | -40.90% | 5.22% | -37.29% | -215.44% |
| Azenta, Inc. (AZTA)vs › | $1.95B | -20.02% | -19.08% | -29.38% | -13.21% |
| Immunome, Inc. (IMNM)vs › | $1.95B | -3059.99% | -3150.18% | -1765.57% | -1177.05% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.94B | -15.82% | -37.57% | -42.30% | -41.11% |
| Alvotech (ALVO)vs › | $2.05B | -36.51% | -21.30% | -316.14% | -299.31% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.09B | -268385.71% | -9751.05% | -6580.61% | -4774.06% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
